Quantum-Si

Quantum-Si, Inc. develops a protein sequencing platform of proteomics. It offers single molecule analysis, and democratizing its use by providing researchers and clinicians access to the proteome. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Guilford, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Quantum-Si reports mixed Q4 results, eyes growth with Carbon launch

Quantum-Si's Q4 2022 earnings call showcased a mix of financial challenges and operational successes. The company's focus on innovation, product development, and commercialization efforts positions it well for future growth and impact in the healthcare industry.

Quantum-Si reports Q1 revenue growth, plans marketing expansion

Quantum-Si's Q1 2023 performance showed promising revenue and customer orders, but challenges persist with high operating expenses leading to an EBITDA loss. The company's focus on innovation and market expansion presents growth opportunities in the coming quarters.

Quantum-Si faces revenue hurdles in Q2 2023 earnings call

Quantum-Si's Q2 2023 performance showed revenue and gross profit figures, but challenges in meeting expectations led to significant losses. The company's strengths lie in the commercial team's positive feedback and strategic hires, while opportunities exist in realignment and disciplined growth strategies. Addressing revenue challenges, R&D alignment, and customer feedback are key priorities for Quantum-Si.

Quantum-Si (QSI) reports Q3 revenue growth and eyes global expansion

Quantum-Si (QSI) shows promising progress in revenue growth, product innovation, and market interest, despite facing challenges in expenses and profitability.
The company's strategic focus on commercializing key products and expanding internationally presents significant growth opportunities in the coming quarters.
Overall, QSI's financial performance, product roadmap, and market strategies position it for future success, pending effective execution and cost management.

Quantum-Si reports Q4 loss, eyes growth with innovative sequencing

Quantum-Si's Q4 2023 performance reflects a focus on innovation and market expansion despite a net loss, with strong revenue guidance for 2024.
The company's strategic strengths lie in its disruptive technology, product development initiatives, and market positioning in key regions.
Challenges in managing expenses and achieving profitability underscore the need for operational efficiency and competitive differentiation.
Amidst challenges, Quantum-Si has opportunities to drive growth through new product launches, market expansion, and meeting increasing market demand.

Quantum-Si reports revenue growth and strategic priorities for 2024

Quantum-Si's Q2 2024 performance showed revenue growth and improved net loss.
The company's strengths lie in financial reserves, guidance, and strategic priorities.
Challenges include managing expenses and balancing financial strength with innovation.
Opportunities arise from new board additions, technology potential, and market focus.

Quantum-Si reports Q3 revenue miss, eyes growth opportunities ahead

Quantum-Si's Q3 2024 performance reflects revenue challenges but anticipates improvement in Q4, supported by strong cash reserves.
The company's strategic strengths include leadership appointments, industry recognition, and initiatives to drive technology adoption.
Addressing challenges in deal execution, cost management, and revenue generation will be crucial for Quantum-Si's financial health and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum-Si, Inc. engages in the development of a proprietary universal single-molecule detection platform to enable Next-Generation Protein Sequencing, the ability to sequence proteins in a massively parallel fashion. It can be used for the study of nucleic acids. Its platform includes Carbon automated sample preparation instrument, Platinum NGPS instrument, Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments. The company was founded by Jonathan M. Rothberg on June 24, 2013 and is headquartered in Branford, CT.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a new paper that was submitted to BioRxiv, demonstrating the capabilities of its proprietary bioinformatics tool called ProteoVue, for detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled “Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS),” highlights the transformative potential of.

Quantum-Si's New Preprint Showcases Advances in Protein Variant Detection using ProteoVue™ Software with Next-Generation Protein Sequencing™

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Quantum-Si Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Expands International Distribution Network.

Quantum-Si Expands International Distribution Network

Does Quantum-Si Incorporated (QSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Quantum-Si Incorporated (QSI) is a Great Choice

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Launches Platinum® New Library Prep Kit, Expanding Access to Next-Generation Protein Sequencing™.

Quantum-Si Launches Platinum® New Library Prep Kit, Expanding Access to Next-Generation Protein Sequencing™

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening.

Quantum-Si Introduces Protein Barcoding Kit for Multiplexed Protein Screening

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024. Quantum-Si's Management team announced Platinum™ Pro, the Company's evolution of Platinum, as well as Proteus™, the Company's new cutting-edge proteomics platform of the future, that is now under development. “We are very excited t.

Quantum-Si Highlights Major Technical Advances, Next-Generation Platform Architecture and New Proteomic Applications at Investor & Analyst Event

NVIDIA

On Wednesday, Quantum-Si Incorporated QSI stock traded over 100% higher after the protein sequencing company announced a collaboration with NVIDIA Corporation NVDA to develop its new proteomics platform, Proteus, and advance Quantum-Si's core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing.

Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis

Avantor Inc.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in t.

Avantor to Distribute Quantum-Si's Next-Generation Protein Sequencing™ Technology

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si's core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leverag.

Quantum-Si to Develop Acceleration Platform and Advance Core Technologies in Collaboration with NVIDIA

SkyWater Technology

BRANFORD, Conn. & BLOOMINGTON, Minn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™ and SkyWaterTechnology (NASDAQ: SKYT), the trusted technology realization partner, announced today they will jointly expand their relationship to support development of Proteus™, Quantum-Si's next-generation platform designed to transform proteomic research. The expanded collaboration will develop the consumable for Proteus that wil.

Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Production Process Critical for Groundbreaking New Proteomics Platform

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si's novel proteomics platform, Proteus™. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves.

Quantum-Si and Planet Innovation to Partner on Proteus™

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has been awarded Frost & Sullivan's prestigious 2024 Technology Innovation Leadership Award in North America. This award recognizes QSI's groundbreaking work in developing the Platinum® instrument, the first benchtop sequencer capable of providing single-molecule resolution at the amino acid level, opening new frontiers for.

Quantum-Si Honored with Frost & Sullivan's 2024 Technology Innovation Leadership Award for Next-Generation Protein Sequencing™

Quantum-Si incorporated (NASDAQ:QSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Doug Farrell - VP, IR Jeffrey Hawkins - President & CEO Jeffry Keyes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the 2024 Third Quarter Quantum-Si Earnings Call.

Quantum-Si incorporated (QSI) Q3 2024 Earnings Call Transcript

Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.15 per share a year ago.

Quantum-Si Incorporated (QSI) Reports Q3 Loss, Lags Revenue Estimates

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024. Press Release Highlights Reported revenue of $787,000 for the third quarter of 2024 Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities Announced appoi.

Quantum-Si Reports Third Quarter 2024 Financial Results

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a newly released preprint publication on BioRxiv, from Dr. Gloria Sheynkman at the University of Virginia School of Medicine. In the publication, Sheynkman and team demonstrate the application of Quantum-Si's Platinum™ single-molecule benchtop sequencer to distinguish proteoform-informative peptides within the human tropomyosin (TPM) ge.

University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si's Next-Gen Protein Sequencer™ Platinum®

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will be participating in two upcoming investment conferences. Jeff Hawkins, Quantum-Si's Chief Executive Officer, will participate in a fireside chat discussion at the UBS Global Healthcare Conference on Wednesday, November 13th, at 8:45 AM PT. On Thursday, November 21st at 8:00 AM ET, Mr. Hawkins will participate in a fireside.

Quantum-Si to Participate in Upcoming Investment Conferences

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Company will host an Investor & Analyst event in New York City on November 20th, 2024. Quantum-Si's management team will provide updates on the Company's evolving technology roadmap, emerging applications for protein sequencing and the expanding commercial opportunities that these innovations create. A live question and ans.

Quantum-Si to Host Investor & Analyst Event in New York City on November 20th, 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced its attendance at the 2024 American Society of Human Genetics (ASHG) Annual Meeting, where it will host a sponsored talk on the role of Next-Generation Protein Sequencing (NGPS) in advancing genomics research. The presentation, titled “From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein.

Quantum-Si to Present at the 2024 American Society of Human Genetics Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--QSI to report Q3 2024 Operating Results on 11/12/24.

Quantum-Si to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BRANFORD, Conn.--(BUSINESS WIRE)--QSI announces inducement grants.

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRANFORD, Conn.--(BUSINESS WIRE)--Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024.

Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si announces proteomics webinar.

Northwestern Proteomics Center of Excellence Partners with Quantum-Si for Webinar on Advancing Proteoform Analysis with Top-Down Mass Spectrometry and Single-Molecule Sequencing

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Liberate Bio, a Boston-based biotech unleashing the potential of genetic medicines with novel delivery vehicles, has integrated the Platinum® Next-Generation Protein Sequencer™ (“NGPS”) into their platform for developing novel gene therapies with improved targeting capabilities. Liberate is using the sequencer's protein barcoding a.

News for Quantum-Si Stock (QSI)